January 31, 2017 07:33 AM ESTUpdated 03:37 PM
Bioregnum
Opinion

Big Phar­ma CEOs get a face-to-face with Trump and a shot at a ne­go­ti­at­ed cease fire

On Mon­day, as CEOs in the biotech in­dus­try chimed in to crit­i­cize Don­ald Trump’s trav­el ban for 7 Mus­lim coun­tries, the top fig­ures from …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

Ex­clu­sive: Two Vi­da Ven­tures co-founders ex­it the VC firm

Cas­es of se­vere RSV in two Mod­er­na vac­cine can­di­dates' tri­als raise ques­tions about fu­ture

Ear­ly da­ta on BTK de­graders sug­gest promise of next-gen ap­proach

UniQure stock dou­bles on FDA 'align­men­t' over ac­cel­er­at­ed ap­proval for Hunt­ing­ton's drug

Wal­greens in talks to sell to pri­vate eq­ui­ty — re­port

sponsored

The key to faster, more im­pact­ful re­search? Put pa­tients in the dri­ver’s seat

A service from the Financial Times